GSK Bio
NEWS
A comprehensive map of genes necessary for cancer survival is one step closer, following the validation of the two largest CRISPR-Cas9 genetic screens in 725 cancer models, across 25 different cancer types.
The FDA issued a Complete Response Letter for its combination treatment of cabotegravir and rilpivirine.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Another recall has been issued for ranitidine tablets due to the presence of a carcinogen contaminant.
GlaxoSmithKline announced results from its pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
Submission follows completion of a Clinical Endpoint study
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
JOBS
IN THE PRESS